In average-risk adults, Cologuard Plus demonstrated sensitivities of 95% for CRC and 43% for advanced precancerous lesions at 94% specificity in the pivotal BLUE-C trial.
The company says the enhanced sensitivity will help minimize unnecessary follow-upEnhanced sample stability components also will give patients more time to return their sample to the lab.BLUE-C study
According to the BLUE-C results, the sensitivities of Cologuard Plus were 95% for CRC and 43% for advanced precancerous lesions, at 94% specificity with no findings on colonoscopy.
Colorectal Cancer (CRC) Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Colonoscopy Bowel Preparation Clinical Guidelines Guidelines Dysplasia U.S. Food And Drug Administration United States Food And Drug Administration Fda Hemoglobin Hb Hemoglobin Hgb Hb - Hemoglobin Indiana Medicare
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer IndicationsSubcutaneous injections save time, taking about 7 minutes, vs 30-60 minutes for intravenous infusion.
Read more »
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast CancerUnlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery.
Read more »
FDA OKs First Treatment for Rare, Deadly Genetic DisorderMiplyffa treats Niemann-Pick disease type C, which progressively impacts the abilities to speak, swallow, and walk or move independently.
Read more »
FDA OKs First-in-Class Antipsychotic for SchizophreniaThe FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
Read more »
A microgrid project at Viejas gets a macro boostThe US Department of Energy OKs a $72.8 million loan for a microgrid project at Viejas
Read more »
Fecal Immunochemical Test Performance for CRC Screening Varies WidelyCommonly used fecal immunochemical tests vary in their performance, which has implications for the benefits and cost-effectiveness of FIT-based CRC screening programs.
Read more »